Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
BICX - BIOCORRX INC
Market Cap 17.44M P/E - EPS this Y - Ern Qtrly Grth -
Income -3.77M Forward P/E -29.43 EPS next Y - 50D Avg Chg 10.00%
Sales 89.16k PEG - EPS past 5Y - 200D Avg Chg 20.00%
Dividend N/A Price/Book N/A EPS next 5Y - 52W High Chg -26.00%
Recommedations - Quick Ratio 0.02 Shares Outstanding 8.82M 52W Low Chg 845.00%
Insider Own 61.24% ROA -404.57% Shares Float 3.53M Beta 0.57
Inst Own - ROE - Shares Shorted/Prior -/- Price 2.06
Gross Margin 59.64% Profit Margin - Avg. Volume 633 Target Price -
Oper. Margin -4,344.24% Earnings Date May 13 Volume 5 Change 0.00%
Healthcare | Medical Care Facilities | United States
About BIOCORRX INC

BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program for substance abuse that includes peer recovery support; and distributes UnCraveRx weight loss management program, a medically assisted weight management program. The company is also developing BICX101, an injectable and implantable naltrexone product; and BICX104, an implantable naltrexone implant for the treatment of opioid addiction and alcoholism. It distributes its program to healthcare providers and licensed healthcare professionals. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. BioCorRx Inc. is based in Anaheim, California.

BIOCORRX INC News
04/03/24 BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
04/02/24 BioCorRx Reports Business Update for 2023
02/28/24 BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
02/08/24 BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
01/09/24 BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
11/14/23 BioCorRx Reports Business Update for the Third Quarter of 2023
08/15/23 BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
08/14/23 BioCorRx Reports Business Update for the Second Quarter of 2023
07/18/23 BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
05/16/23 BioCorRx Provides Business Update for the First Quarter of 2023
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Lucido Louis C. Director Director Jan 24 Buy 1.20 200 240 101,259 01/25/23
Lucido Louis C. Director Director Jan 13 Buy 1.13 4,000 4,520 101,059 01/17/23
Lucido Louis C. Director Director Dec 12 Buy 0.84 5,000 4,200 89,425 12/15/22
Lucido Louis C. Director Director Aug 29 Buy 2.11 3,878 8,183 80,385 08/31/22
Lucido Louis C. Director Director Aug 25 Buy 2.15 1,060 2,279 76,507 08/29/22